Moderna

Today we announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19  vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for…

For Jagjit Ludu, joining Moderna meant the chance to think differently and connect science to people in new ways. From launching clinician-focused docu-series to building AI-powered tools for bite-sized learning, he’s reshaping how Medical Affairs engages and informs. 💡 “Being…

We are proud to share the results of our mRNA-1283 Phase 3 trial in @TheLancetInfDis. Read more: thelancet.com/journals/lanin…

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. Our COVID-19 vaccine,…

Today we announced positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy against influenza illness of mRNA-1010, our seasonal influenza vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and…

We announced today that the U.S. FDA has approved mRESVIA®, our respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 18–59 years of age who are at increased risk for disease. This approval expands the…

mNEXSPIKE® (COVID-19 vaccine, mRNA) is now approved in the U.S., marking our third approved product. We are proud of our platform’s continued impact, and our relentless commitment to excellence. Read more from our CEO Stéphane Bancel about this approval, and what’s next:…

We announced today that the U.S. FDA has approved mNEXSPIKE®, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes…

Today we announced an update on our investigational pandemic influenza program. Learn more: lnkd.in/ekEJnH9v.

Today we announced that we have submitted an application to the U.S. Food and Drug Administration for review of our Spikevax 2025-2026 formula, a COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1. Read more: lnkd.in/esTqSGJn.

Today we announced an update on our BLA submission for our combination vaccine against influenza and COVID-19. Read more: investors.modernatx.com/news/news-deta…

Today, on #ClinicalTrialsDay, we pause to thank the people who make progress in medicine possible. To the participants who lend their time, trust and courage. To the researchers who push the boundaries of science. To the coordinators, nurses and support staff who keep it all…

Earlier today, we reported financial results and provided business updates for the first quarter of 2025. For the latest episode of our #IRInsights series, members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage…

Today, we reported financial results and provided business updates for the first quarter of 2025. Read more: investors.modernatx.com/news/news-deta…

At Moderna, we recognize that human and planetary health are interconnected—and that we have a responsibility to grow in a way that protects the planet and minimizes our environmental impact. To celebrate Earth Day, colleagues from our Cambridge, Massachusetts, office rolled up…

We announced today that Moderna will deliver twelve scientific presentations at the ESCMID Global Congress in Vienna, Austria, April 11–15, 2025.  This includes three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of our…

Have you ever wondered what happens when you're infected with a virus like the #flu, or SARS-CoV-2? How does it multiply and spread in your body? Watch this video to learn how your own cellular machinery fuels the spread of viruses. You can also head to Module 1 on our free…

We announced today that the Australian Therapeutic Goods Administration has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older. Read…